These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 25577263)

  • 21. [Bone remodeling: new therapeutic approaches].
    Ferrari S
    Rev Med Suisse; 2009 Jun; 5(207):1325-8. PubMed ID: 19626933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Removing the bone brake.
    Schett G; Bozec A
    Cell Metab; 2014 Sep; 20(3):394-5. PubMed ID: 25185946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Reducing bone resorption by cathepsin K inhibitor and treatment of osteoporosis].
    Watanabe R; Okazaki R
    Clin Calcium; 2014 Jan; 24(1):59-67. PubMed ID: 24369281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone biology, signaling pathways, and therapeutic targets for osteoporosis.
    Iñiguez-Ariza NM; Clarke BL
    Maturitas; 2015 Oct; 82(2):245-55. PubMed ID: 26255682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation.
    Marie PJ
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S11-5. PubMed ID: 16735840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Osteoanabolics and the forthcoming drugs for the treatment of osteoporosis].
    Grazio S
    Reumatizam; 2014; 61(2):95-9. PubMed ID: 25427402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)].
    Quemerais-Durieu MA; Kerlan V; Chabre O
    Ann Endocrinol (Paris); 2011 Oct; 72 Suppl 1():S15-22. PubMed ID: 22008272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological agents in management of osteoporosis.
    Tella SH; Gallagher JC
    Eur J Clin Pharmacol; 2014 Nov; 70(11):1291-301. PubMed ID: 25204309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteoporosis: Mechanism, Molecular Target and Current Status on Drug Development.
    Li H; Xiao Z; Quarles LD; Li W
    Curr Med Chem; 2021; 28(8):1489-1507. PubMed ID: 32223730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Osteoporosis: From Molecular Mechanisms to Therapies.
    Tang CH
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Odanacatib for the treatment of osteoporosis.
    Boggild MK; Gajic-Veljanoski O; McDonald-Blumer H; Ridout R; Tile L; Josse R; Cheung AM
    Expert Opin Pharmacother; 2015; 16(11):1717-26. PubMed ID: 26149759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Pathophysiology and Treatment of Osteoporosis.
    Drake MT; Clarke BL; Lewiecki EM
    Clin Ther; 2015 Aug; 37(8):1837-50. PubMed ID: 26163201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Future therapeutic targets in osteoporosis.
    Deal C
    Curr Opin Rheumatol; 2009 Jul; 21(4):380-5. PubMed ID: 19461517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cathepsin K inhibitors: a novel target for osteoporosis therapy.
    Stoch SA; Wagner JA
    Clin Pharmacol Ther; 2008 Jan; 83(1):172-6. PubMed ID: 18073778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of cathepsin K for treatment of osteoporosis.
    Boonen S; Rosenberg E; Claessens F; Vanderschueren D; Papapoulos S
    Curr Osteoporos Rep; 2012 Mar; 10(1):73-9. PubMed ID: 22228398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting WNT signaling in the treatment of osteoporosis.
    Baron R; Gori F
    Curr Opin Pharmacol; 2018 Jun; 40():134-141. PubMed ID: 29753194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of bisphosphonates on osteoporosis: Focus on zoledronate.
    Oryan A; Sahvieh S
    Life Sci; 2021 Jan; 264():118681. PubMed ID: 33129881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling.
    Riggs BL; Parfitt AM
    J Bone Miner Res; 2005 Feb; 20(2):177-84. PubMed ID: 15647810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether we are addressing them.
    Gasser JA
    Curr Opin Pharmacol; 2006 Jun; 6(3):313-8. PubMed ID: 16650802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Newly developed drugs to improve bone strength].
    Hagino H
    Clin Calcium; 2016 Jan; 26(1):99-105. PubMed ID: 26728536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.